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Abstract
Transformations that selectively modify the furan ring present in a variety of naturals products
would be useful in the synthesis of biological probes but remain largely underexplored. The
neoclerodane diterpene salvinorin A, isolated from Salvia divinorum, is an example of a furan-
containing natural product. Following selective bromination of salvinorin A, Suzuki-Miyaura and
Sonogashira couplings were accomplished in moderate to good yields without hydrolyzing the
labile C-2 acetate or altering the stereochemistry of the epimerizable centers.
Natural products (NPs) play an important role in drug discovery, serving as either a source
or inspiration for approximately half of all approved small-molecule drugs.1 Although a
large number of these drugs are naturally occurring substances, derivatives of NPs are often
necessary to improve pharmacokinetic properties. These derivatives have traditionally been
accessed through total synthesis2 and mutasynthesis.3 In cases where the NP is readily
available from the natural source, semisynthesis is an attractive approach. Due to the large
and often complex scaffolds nature develops, semisynthesis requires highly selective
transformations.
Perhaps the best examples of NP derivatives that have been developed into drugs are the
many opioids prescribed for the treatment of pain.4 While these treatments have proved
successful, their action at the µ opioid receptor makes them prone to addiction. The κ opioid
receptor (KOR) has been proposed as an alternative target for the treatment of pain.
However, agents that exert their effects on this receptor are prone to central side-effects
including sedation and dysphoria. New KOR probes are needed to better understand the
mechanism associated with these side-effects.
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The perennial sage Salvia divinorum, a plant traditionally used in divination rituals by the
indigenous people of Oaxaca, Mexico has recently gained attention amongst recreational
drug users due to the intense hallucinations produced upon inhalation of the pyrolized
leaves. The major psychoactive component, salvinorin A (1), produces these effects by
selectively activating the KOR,5a making it the first non-nitrogenous opioid receptor
agonist. As a result, several binding models have been suggested to explain how 1 interacts
with the KOR while lacking a basic nitrogen.5
To complement these models, several studies have produced a number of analogues of 1.6
These semisynthetic derivatives were synthesized by selectively altering the many
functional groups present in 1. Thus the structure-activity relationships (SAR) regarding the
C-2 acetate and C-4 carbomethoxy positions have been thoroughly investigated. In contrast,
the lack of chemical handle on the furan ring has limited derivatives with the furan ring
intact to only a few examples. Since all proposed binding models have implicated the furan
ring, such derivatives would be useful in elucidating additional SAR.
The modification of NPs containing aromatic functionalities has been accomplished by first
introducing a halide using enzymatic3 or chemical methods.7 The resulting halides were
further diversified using various palladium-catalyzed transformations. Despite the large
number of examples,8 this approach has not been applied to furan-containing NPs. Such a
method would be useful as this may lead to analogues with improved drug-like properties
not just improved potency. The furan ring of 1 was previously brominated selectively at the
C-16 position using NBS,9 however these reaction conditions required long reaction times
and produced either low or highly variable yields. The addition of a catalytic amount of Br2
reduced the reaction time to 30 minutes and consistently provided yields of 49% (Scheme
1). The resulting product 2 was spectroscopically identical to previous reports and the site of
bromination was confirmed by single crystal X-ray diffraction.10 It is not clear at this time
why the addition of catalytic Br2 improves the reactivity for the selective bromination. One
possibility is that the Br2 and NBS form a reactive complex but this suggestion will require
additional investigation.
With rapid access to 2, investigations into further modifications were initiated using Suzuki-
Miyara couplings due to their relatively mild reaction conditions. Utilizing the reaction
conditions developed by Buchwald11 produced a complex mixture with two major isomeric
products, surprsingly with the base labile C-2 acetate group intact (Scheme 2).1H-NMR
revealed the products to be the C-8 epimers 3a and 4a. Epimerization at the C-8 position is
well-documented in both semisynthetic12 and total synthesis13 efforts, occurring under both
acidic and basic conditions. Furthermore, 8-epi-1 is also found in the smoke of pyrolized S.
divinorum.14 This epimerization has profound biological impact as 8-epi-1 and its
derivatives generally exhibit decreased affinity and efficacy at the KOR.12 Thus reaction
conditions that reduce C-8 epimerization were desired to obtain the necessary quantites of
biologically useful probes.
Noting that the formation of 4a is likely controlled by either base or heat, the amount of
K3PO4 added and reaction temperature were varied to minimize epimerization (Table 1).
Although reducing the amount of base in the reaction did improve the ratio of 3a/4a, the
accompanying decrease in conversion required extensive chromatography to separate 2 and
3a. Fortunately, reducing the reaction temperature to 60°C resulted in full conversion and
>99:1 selectivity for 3a over 4a
Having optimized the conditions to prevent epimerization, our attention turned to exploring
the scope of the reaction (Table 2). In addition to simple phenyl and naphthyl groups, phenyl
rings bearing substitutions in the ortho, meta, and para position were possible. As expected,
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electron-rich boronic acids typically produced higher yields than electron-deficient ones.
Furans substituted at either the 2- or 3-position and a 3-thiophene could be appended to C-16
in moderate yields, however 2-thienyl and 2-pyridinyl boronic acids produced no reaction.
In the case of the thiophene, this could be overcome using a MIDA boronate developed by
Burke,15 however the reaction was incomplete even after 24 hours. Despite several attempts
using 2-pyrdinyl MIDA boronate, 3v was never successful formed. It is possible that indoles
and other azole coupling partners may be more successful. Finally, alkenyl and alkylboronic
acids produced moderate to good yields of the corresponding products. In the case of
phenethyl boronic acid, the expected product was also accompanied by 13% of 1,
presumably from protodebromination.
In addition to monobromination of the furan ring, dibromination can be accomplished by
using a stoichiometric amount of bromine. In order to test whether there was any inherit
selectivity for the coupling reactions, the dibrominated product (5) was submitted to same
reaction conditions using only 1 equivalent of PhB(OH)2. Interestingly the diarylated
product was the only product observed, producing nearly a 1:1 mixture of recovered starting
material and 6 (Scheme 3). The lack of either monosubstituted product suggests that the
second coupling reaction is faster than the first.
To extend the method from sp2- and sp3-hybridized substitutions to alkyne substitutents,
Sonogashira couplings were also investigated. Employing conditions previously used for
Sonogashira couplings on bromofurans,16 several alkynyl substitutions were synthesized
(Table 3). Despite an increase in the reaction temperature and large excess of base, no
epimerization was observed. Terminal alkynes bearing aromatic rings, both electron-rich
and electron-poor, and alkyl chains were appended to furan ring of 1. To access a terminal
alkyne, ethynyltrimethylsilane was used however this reaction produced an inseparable
mixture of TMS-protected 7f and 2. Treating this mixture with TBAF in CH2Cl2 allowed for
facile isolation of 7f by column chromatography.
A representative portion of the derivatives were screened for activity at the KOR using a
calcium mobilization assay (Table 4).17 Based on these preliminary results, it appears as
though some substitutions at the C-16 position are tolerated. Particularly interesting is 3s
which is equipotent with 1. However the compound with the inverted stereochemistry at C-8
(4a) possessed a significant decrease in potency, thus verifying the importance of preventing
C-8 epimerization.12b
In conclusion, using Suzuki-Miyaura and Sonogashira couplings, a variety of alkyl, alkenyl,
aryl, heteroaryl, and alkynyl substituents were appended to the C-16 position of 1. Due to
the many functional groups present in 1, these transformations required a high degree of
chemoselectivity. The resulting derivatives provide access to furan ring-containing probes
that have, until now, remained underexplored. The corresponding pharmacological data,
which will be presented in due course, should offer valuable insight into how 1 interacts
with the KOR. Furthermore, this highly amenable process will be applied to the synthesis of
biological probes using other furan-containing NPs.
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Improved Selective Bromination of 1
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Initial Suzuki-Miyaura Reaction Using 2
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Dibromination and Arylation of 1
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Table 1









1 3.0 100 100 12:1
2 2.5 100 91 80:1
3 2.0 100 17 >99:1
4 3.0 60 100 >99:1
a
Conversion measured by GC-MS
b
Ratio of 3a/4a measured by HPLC.
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Table 3
Sonogashira Couplings of 2










Isolated yield after treatment with TBAF
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Table 4
Selected KOR Activity Data




1 1 29 ± 6 95 ± 5
2 3a 72 ± 11 101 ± 4
3 4a 3451c 91
4 3g 971 ± 45 111 ± 3
5 3p 145 ± 40 72 ± 2
6 3s 29.8 ± 3.4 115 ± 7
a
EC50 = Effective concentration for 50% maximal response. Data are from at least 3 independent experiments.
b
Emax = % which compound stimulates compared to (−)-U69,593.
c
n = 1.
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